CalciMedica Secures Up to $49M in Private Placement, Extends Runway, and De-risks Key Clinical Trial

summarizeSummary

CalciMedica secured up to $49 million in a private placement, including $15 million upfront at a premium to market, with significant insider participation, extending its cash runway into the second half of 2027 and addressing prior going concern doubts. This capital will fund a new strategic focus on pulmonary hypertension, while the FDA also cleared its Auxora AKI trial to proceed after a safety review.

check_boxKey Events · Financing and Capital Events · CALC

• Significant Private Placement Secured

  CalciMedica entered into a private placement agreement for approximately $15.0 million in upfront gross proceeds, with the potential for an additional $34.0 million if warrants are fully exercised, totaling up to $49.0 million. The offering was priced at $0.8033 per common stock unit, a premium to the current market price of $0.625.

• Insider Participation in Financing

  The Chief Executive Officer, Chief Business Officer, Chief Medical Officer, and an affiliate of a Director participated in the private placement, investing in an aggregate of 6,908,996 units, demonstrating strong insider conviction.

• Extended Cash Runway

  The net proceeds from the private placement, combined with existing cash, are expected to fund operations into the second half of 2027, addressing prior concerns about the company's ability to continue as a going concern.

• FDA Clears KOURAGE Trial to Proceed

  The FDA reviewed a protocol amendment and interim safety data for the Phase 2 KOURAGE trial (Auxora in acute kidney injury) and provided no comments or questions, allowing clinical development to continue after a previous enrollment pause related to a mortality imbalance.

auto_awesomeAnalysis · CALC · Life Sciences

This is a critical financing event for CalciMedica, a micro-cap biotech that previously disclosed "substantial doubt" about its ability to continue as a going concern. The company successfully raised $15 million upfront, with the potential for an additional $34 million from warrant exercises, providing a cash runway into the second half of 2027. The offering was priced at a premium to the current market price, and saw significant participation from the CEO, CBO, CMO, and a director's affiliate, signaling strong insider confidence. Concurrently, the FDA cleared the Phase 2 KOURAGE trial for Auxora in acute kidney injury to proceed after reviewing a protocol amendment and interim safety data, removing a significant clinical overhang. The proceeds will also enable a new strategic focus on pulmonary hypertension, with a Phase 1b study for Auxora and IND clearance for CM5480 planned.